501-3292
Production Way, Burnaby, B.C., V5A 4R4
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix
Technologies Granted
Cannabis Drug Detection Device Canadian
Patent,
Delivers THCBA to US Clinic
Cannabix
is developing
Marijuana
Breathalyzer
devices to
give law enforcement and employers
a
tool to
enhance
public safety
Vancouver, British
Columbia -- July
6,
2021 -- InvestorsHub
NewsWire -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the
"Company"
or
"Cannabix")
developer of the
Cannabix Marijuana Breathalyzer devices for law enforcement and the
workplace, announces that
the
Canadian
Intellectual Property Office (CIPO)
has
granted patent No.
2887841
entitled, "Cannabis
Drug Detection Device". The Company has
been pursuing this original patent application since its filing on
April 16, 2015. Cannabix
Technologies is
on the
forefront in research and
development to create
point-of-care
breath
testing
technologies for
the
detection of ?9-tetrahydrocannabinol
("THC") - the psychoactive
component of marijuana that causes impairment.
"Similar
to our USPTO patent, the intellectual
property protection this THC detection patent covers, gives
Cannabix a broad foundation to build upon in view of the formidable
insights and technical advancements made in the field of molecular
gas analysis at atmospheric pressure that we have developed since
this patent was initially filed in 2015.
This
patent is a useful plank
in our
IP protection strategy" said Dr. Raj
Attariwala.
The
Company
also reports that in June it delivered its
THC
Breath Analyzer ("THCBA")
to a
clinic in the Northwestern,
U.S. for beta
testing. The collaborating
clinic has a robust drug testing operation and is one of the top
drug testing providers to employers within its respective
state. Beta-testing of
the THCBA
prototype
is
focused
on improving user and
administrator experience,
identifying cross-reactivity
of
other
substances within a
semi-controlled
study
population and to
further
train the device's
machine learning database and sensitivity
profile. The THCBA is a drug
screening device for employers and other markets who are seeking a
way to quickly, easily and non-invasively test for recent use
of THC.
"In
the last several months we have seen the states of Oregon, New
Jersey, New York and Arizona legalize recreational use of marijuana
and several other states like Virginia, New Mexico, Montana and
Connecticut have taken steps to either legalize or decriminalize
cannabis possession in some way. This has led to recent reports
from AAA and IIHS outlining the impact of driving performance under
the influence of cannabis. Furthermore,
employers are
re-examining their drug testing policies, procedures and tools.
There is a massive sea-change
happening in the U.S. related to cannabis use and Cannabix
Technologies is at the forefront of developing the tools to
aid
public
safety
and
create more relevant
and
fairer cannabis testing technology", stated CEO, Rav
Mlait.
About Cannabix
Technologies Inc.
Cannabix
Technologies Inc. is a developer of marijuana breathalyzer
technologies for law enforcement and the workplace. Cannabix is
working to develop drug-screening devices that will detect
THC - the psychoactive
component of marijuana that causes impairment using breath samples.
Breath testing for THC would allow employers and law
enforcement to identify
recent marijuana use that better
aligns with impairment.
We seek Safe
Harbor.
On
behalf of the Board of Directors
"Rav
Mlait"
CEO
Cannabix
Technologies Inc.
For further information, contact the Company at
info@cannabixtechnologies.com
The
CSE has not reviewed and does not accept responsibility for the
adequacy or accuracy of this release.
Cautionary
Statement Regarding Forward-Looking Statements
This press release
contains forward-looking information that involves various risks
and uncertainties regarding future events. Such forward-looking
information can include without limitation statements based on
current expectations involving a number of risks and uncertainties
and are not guarantees of future performance of the Company, such
as final development of a commercial or prototype product(s),
successful trial or pilot of company technologies, no assurance
that commercial sales of any kind actually materialize; no
assurance the Company will have sufficient funds to complete
product development. There are numerous risks and uncertainties
that could cause actual results and the Company's plans and
objectives to differ materially from those expressed in the
forward-looking information, including: (i)
adverse market conditions; (ii) risks regarding protection of
proprietary technology; (iii) the ability of the Company to
complete financings; (iv) the ability of the Company to develop and
market its future product; and (v) risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements
and filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing "patent pending" technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.